Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

 
• By Joseph Haas
Pfizer sign
Pfizer puts hopes for oral GLP-1 agonist on daily formulation work

More from Clinical Trials

More from R&D